| mitoxantrone / Generic mfg. |
2004-004903-39: A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis. |
|
|
| Ongoing | 4 | 60 | Europe | Mitoxantrone, Glatiramer Acetate, Interferon Beta 1a, , Injection*, Mitoxantrone, Copaxone, Rebif 44 | The Walton Centre for Neurology and Neurosurgery | Early, active relapsing remitting Multiple Sclerosis (RRMS) | | | | |
ChiCTR-TRC-09000504: Therapeutic role of homoharringtonine in acute promyelocytic leukemia, an open label randomised controlled trial |
|
|
| Completed | 4 | 100 | | Induction therapy with combination of arsenic trioxide and homoharringtonine. After achieved CR, patients receive consolidation treatment with combination of cytarabine and homoharringtonine. All patients in the different groups receive the same maintenance therapy ;Induction therapy with combination of arsenic trioxide and daunorubicin. After achieved CR, patients receive consolidation treatment with combination of cytarabine and daunorubicin or mitoxantrone. All patients in the different groups receive the same maintenance therapy. ;Induction therapy with combination of all-trans retinoic acid and homoharringtonine. After achieved CR, patients receive consolidation treatment with combination of cytarabine and homoharringtonine. All patients in the different groups receive the same maintenance therapy ;Induction therapy with combination of all-trans retinoic acid and daunorubicin. After achieved CR, patients receive consolidation treatment with combination of cytarabine and daunorubicin or mitoxantrone. All patients in the different groups receive the same maintenance therapy | Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Science; Level of the institution：, Self-finance | acute promyelocytic leukemia | | | | |
2008-006342-25: ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone (M) in previously untreated chronic lymphocytic leukaemia |
|
|
| Ongoing | 4 | 218 | Europe | Rituximab (MabThera), Fludarbine (Fludara Oral), Fludarabine (Fludara), Cyclophosphamide Tablets, Cyclophosphamide injection, Mitoxantrone, MabThera, Mitoxantrone, MabThera, Mitoxantrone | Leeds Teaching Hospitals NHS Trust | Chronic Lymphocytic Leukaemia | | | | |
2009-010998-20: Attenuated dose Rituximab with ChemoTherapy In CLL:A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) tocompare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR) |
|
|
| Ongoing | 4 | 206 | Europe | Rituximab (MabThera), Fludarabine (Fludara Oral), Cyclophosphamide Tablets, Fludarabine (Fludara), Mitoxantrone, Rituximab (MabThera or Rituxan) (Reduced dose), Cyclophosphamide injection, MabThera, Mitoxantrone, MabThera, Mitoxantrone | Leeds Teaching Hospitals NHS Trust | Chronic Lymphocytic Leukaemia | | | | |
| Ongoing | 4 | 800 | Europe | Obinutuzumab, Fludarabine, Fludarabine (IV), Cyclophospamide (oral), Cyclophosphamide (IV), Rituximab, Bendamustine, Mitoxantrone, Alemtuzumab, Ofatumumab, Concentrate for solution for infusion, Film-coated tablet, Powder for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Obinutuzumab, Fludarabine (oral), Ofatumumab | University of Leeds, Napp Pharmaceuticals | Chronic lymphocytic leukaemia (CLL), Chronic lymphocytic leukaemia (CLL), Diseases [C] - Cancer [C04] | | | | |
NCT03026842: Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) |
|
|
| Active, not recruiting | 4 | 180 | RoW | Decitabine, Daunorubicin, Cytarabine, Mitoxantrone, Cytarabine, Aclacinomycin, Cytarabine | The First Hospital of Jilin University, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Jilin University, Jilin University | Acute Myeloid Leukemia | 12/23 | 10/24 | | |
| Not yet recruiting | 4 | 60 | | Dexamethasone + tofacitinib ;Tofacitinib + etoposide + dexamethasone ;High-dose decitabine ;gemcitabine + mitoxantrone + oxaliplatin + dexamethasone | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Top Young Talents Program of Hubei Province 2021 | hemophagocytic lymphohistiocytosis | | | | |
ChiCTR2300073612: A single-center, randomized, open, blank parallel controlled clinical study on the efficacy and safety of Mitoxantrone Hydrochloride Injection for Tracing in patients with thyroid cancer undergoing different surgeries |
|
|
| Not yet recruiting | 4 | 408 | | Mitoxantrone Hydrochloride Injection for Tracing was used ;Mitoxantrone Hydrochloride Injection for Tracing was used ;NONE ;NONE | Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University; Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Zhejiang China Resources Jiuzhong Pharmaceutical Co.,Ltd. | thyroid cancer | | | | |
